Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Ken Ito1,2 · Satoshi Yuki2 · Hiroshi Nakatsumi2 · Yasuyuki Kawamoto1 · Kazuaki Harada2 · Shintaro Nakano2 · Rika Saito1 · Takayuki Ando4 · Kentaro Sawada5 · Masataka Yagisawa6 · Atsushi Ishiguro7 · Masayoshi Dazai8 · Ichiro Iwanaga9 · Kazuteru Hatanaka10 · Atsushi Sato11 · Ryusuke Matsumoto12 · Yoshiaki Shindo13 · Miki Tateyama14 · Tetsuhiro Muranaka15 · Masaki Katagiri16 · Isao Yokota17 · Yuh Sakata18 · Naoya Sakamoto2 · Yoshito Komatsu1

Received: 28 October 2021 / Accepted: 24 February 2022 / Published online: 15 March 2022 © The Author(s) 2022

Abstract

Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer.

Methods This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks.

Results From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 μg/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. \( P = 0.846 \)). The changes in mean serum zinc levels after 12 weeks were \( -3.8 \), \( +14.3 \), and \( +46.6 \) μg/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (\( P = 0.045 \)).

Conclusion There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia.

Trial registration. UMIN000039653. Date of registration: March 2, 2020.

Keywords Dysgeusia · Taste disorder · Chemotherapy · Gastrointestinal cancer · Polaprezinc · Zinc acetate hydrate

Introduction

The development of antitumor agents and overall survival in gastrointestinal cancer patients has dramatically improved in the last decade. Increased treatment duration, quality of life (QOL), and management of adverse events has become increasingly important. Diet is an important factor in QOL maintenance, but adverse events of chemotherapy including anorexia, nausea, vomiting, and dysgeusia reduce oral intake [1–4]. Although prevention and treatment have been established for chemotherapy-induced nausea, vomiting, and oral mucositis, there is currently no successful intervention for dysgeusia [5, 6]. The incidence of chemotherapy-induced dysgeusia is around 30–85% [7–17], with moderate-to-severe cases occurring in around 38% of patients [10, 12]. Fluoropyrimidines and platinum-based drugs, which are often used for gastrointestinal cancers, cause dysgeusia in 48.1% and 42.1% of patients, respectively [16]. Long-term dysgeusia may lead to poor nutritional and performance status [1]. Although the precise mechanisms underlying
chemotherapy-induced dysgeusia remain unclear, inhibition of differentiation and proliferation of cells in the taste buds via direct toxic action of chemotherapy drugs or neurotoxic effects of chemotherapy may be implicated in the etiology of dysgeusia [7, 18, 19].

Zinc deficiency due to chelation by chemotherapeutic agents may also contribute to the etiology of chemotherapy-induced dysgeusia [4, 18]. High amounts of zinc are required to regenerate the cells in taste buds, indicating that zinc deficiency may cause dysgeusia [20]. Ikeda et al. [21] reported that oral administration of polaprezinc (zinc-
-l-carnosine) in patients with zinc deficiency or idiopathic dysgeusia increased plasma zinc levels and improved dysgeusia. Therefore, zinc supplementation is likely to be effective in alleviating dysgeusia. However, most studies on the effects of zinc supplementation on chemotherapy-induced dysgeusia have been small retrospective studies [17, 22–25], and there have been no prospective multicenter studies. The relationship between improvement of dysgeusia and zinc supplementation remains unclear. Therefore, we designed a multicenter, prospective observational study to examine the effect of zinc therapy on chemotherapy-induced dysgeusia in patients with gastrointestinal cancer.

**Materials and methods**

**Study design and patients**

The present investigator-initiated, multicenter, and prospective observational study recruited patients undergoing chemotherapy at 17 institutes in Japan from February 2020 to June 2021. Eligibility criteria included patients presenting with grade ≥ 1 dysgeusia according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [26] or Scale of Subjective Total Taste Acuity (STTA) [27] during chemotherapy for gastrointestinal cancer (including esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer). The exclusion criteria were administration of zinc preparations before registration and history of head and neck radiation therapy. The enrolled patients were treated for dysgeusia using one of the following methods: no intervention, zinc acetate hydrate (50–100 mg of zinc per daily normal dose), or polaprezinc (34.1 mg of zinc per daily normal dose). Treatment for dysgeusia was determined by the attending physician. In Japan, many patients with chemotherapy-induced dysgeusia do not receive any therapeutic intervention; therefore, a no intervention group was included in the present study. After registration, physicians collected clinical information related to dysgeusia prospectively for 12 weeks using blood sampling and two questionnaires at the beginning and end of treatment.

**Assessment of serum zinc levels, dysgeusia, QOL, and safety**

Serum zinc levels were measured at weeks 0 (enrollment), 6, and 12. Absolute changes in serum zinc levels were calculated by subtracting the value obtained at enrollment from those obtained at weeks 6 and 12 after enrollment. Serum copper levels and nutritional factors, such as hemoglobin and albumin, were also measured at the same time as serum zinc levels, and absolute changes in these were defined in the same way. Vitamin B12 levels were also measured at enrollment and after 12 weeks.

Clinical information related to dysgeusia was collected from patients for 12 weeks after registration. Dysgeusia was graded according to the CTCAE v5.0, STTA, Visual Analog Scale (VAS), and Chemotherapy-induced Taste Alteration Scale (CiTAS) criteria [28]. This information was collected twice using questionnaires at enrollment and after 12 weeks. Efficacy rates (%) for CTCAE and STTA scores were calculated by dividing the number of patients whose scores were cured or improved by the total number of patients who participated in each dosage group. QOL was graded according to the quality-of-life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD). This information was included in the dysgeusia questionnaires and collected at enrollment and after 12 weeks. The incidence of adverse effects due to zinc replacement therapy was analyzed statistically.

**Statistical analysis**

Absolute changes in the serum zinc levels in each group were compared using Wilcoxon’s signed rank test. Absolute changes in the serum zinc levels of patients in the zinc acetate hydrate and polaprezinc groups relative to the non-intervention group were compared using Steel’s multiple comparison. Improvement in dysgeusia was determined by comparing CTCAE v5.0 and STTA using chi-square test, and the extent of change in VAS and CiTAS was compared using Steel’s multiple comparison test. Change in QOL-ACD was compared using Steel’s multiple comparison test. The objective variable was improvement of dysgeusia, the explanatory variable was the range of change of each factor, and multivariate analysis (multiple regression analysis and logistic regression analysis) was used to investigate the independent factors related to the improvement of dysgeusia, respectively. Among the few small retrospective studies on the efficacy of zinc preparations in chemotherapy-induced dysgeusia, the improvement rate was reported to be around 60–70% [17, 23, 25]. A multicenter, placebo-controlled, double-blind study
evaluating the efficacy of zinc preparations in dysgeusia excluding malignancy reported an efficacy rate of 61.9% for zinc preparations compared with 39.5% for placebo [21]. The sample size was set to 60 per group due to feasibility. This size was calculated to be adequate to achieve a statistical power of 80% with significance level of 5% under the improvement rates of 65% and 40% in dysgeusia with zinc preparation and no treatment, respectively. Statistical analyses were performed using JMP 14 (SAS Institute Inc., Cary, NC, USA). All P-values > 0.05 were considered significant.

Results
Patient characteristics

The enrolled institutions and the number of patients enrolled at each institution are shown in Online Resource 1. Among a total of 180 patients enrolled in the study, five were excluded due to noncompliance with the participation criteria (four patients had grade 0 CTCAE and STTA, and one had neuroendocrine carcinoma), and three patients in the no intervention group began receiving zinc therapy. Thus, the final total of patients eligible for evaluation in the present study included 53 in the no intervention group, 60 in the zinc acetate hydrate group, and 59 in the polaprezinc group. The characteristics of the 172 patients who participated in the study are summarized in Table 1. There were more females in the no intervention group (male/female: 25/28) and more males in the zinc acetate hydrate and polaprezinc groups (male/female: 42/28, 36/24, respectively). The median age of the polaprezinc group was 67 years, which was slightly younger than that of the no intervention and zinc acetate hydrate groups, which was 70 years. The mean serum zinc levels at baseline were 67.3 μg/dL (95% confidence interval (CI), 63.0–71.6 μg/dL) in the no intervention group, 67.5 μg/dL (95% CI, 63.9–71.1 μg/dL) in the zinc acetate hydrate group, and 65.2 μg/dL (95% CI, 60.9–70.6 μg/dL) in the polaprezinc group.

| n (%) | No intervention (n = 53) | Zinc acetate hydrate (n = 60) | Polaprezinc (n = 59) |
|-------|------------------------|-----------------------------|---------------------|
| Sex   | Male 25 (47)           | 42 (70)                     | 36 (61)             |
|       | Female 28 (53)         | 18 (30)                     | 23 (39)             |
| Age   | Median (range) 70 (27–86) | 70 (42–81)                 | 67 (40–79)          |
| Body mass index | Median (range) 21.0 (14.6–33.5) | 21.9 (16.2–30.7) | 21.9 (15.4–30.5) |
| ECOG PS | 0 28 (53)             | 37 (62)                     | 35 (59)             |
|       | 1 24 (45)             | 23 (38)                     | 24 (41)             |
|       | 2 1 (2)               | 0 (0)                       | 0 (0)               |
| Professional oral care* | Yes 18 (34)         | 26 (43)                     | 20 (34)             |
|       | No 35 (66)            | 34 (57)                     | 39 (66)             |
| Mouth rinses | Yes 27 (51)       | 39 (65)                     | 32 (54)             |
|       | No 26 (49)            | 21 (35)                     | 27 (46)             |
| Duration of dysgeusia (day) | Median (range) 36 (1–1.933) | 23 (1–1.167) | 29 (1–3.697) |
| Cancer site | Esophagus 2 (4) | 1 (2)                       | 0 (0)               |
|       | Gastric 15 (28)       | 12 (20)                     | 14 (24)             |
|       | Colorectal 26 (49)    | 28 (47)                     | 30 (51)             |
|       | Pancreatic 6 (11)     | 12 (20)                     | 7 (12)              |
|       | Biliary tract 4 (8)   | 6 (10)                      | 7 (12)              |
|       | Others 0 (0)          | 1 (2)                       | 1 (2)               |
| Chemotherapy drugs | Platinum 28 (53) | 30 (50)                     | 35 (59)             |
|       | Fluoropyrimidines 38 (72) | 48 (80)          | 45 (76)             |
|       | Taxanes 10 (19)       | 8 (13)                      | 7 (12)              |
| Number of pretreatments | 0 37 (70)         | 41 (68)                     | 41 (69)             |
|       | 1 17 (28)             | 12 (20)                     |                   |
|       | ≥2 5 (9)              | 2 (3)                       | 6 (10)              |
| Serum zinc (μg/dL) | Median (range) 68/29–113 | 64/43–109                  | 66/25–109           |
| Hb (g/dL) | Median (range) 11.2 (8.3–16.1) | 11.5 (8.1–16.4) | 11.0 (8.0–16.2) |
| Alb (g/dL) | Median (range) 3.6 (2.1–4.5) | 3.7 (2.6–4.5) | 3.5 (2.4–4.5) |
| Ferritin (ng/mL) | Median (range) 129.5 (3.7–1855) | 155.1 (7–1343) | 97.2 (4–1051) |
| Vit B12 (pg/mL) | Median (range) 457 (110–1500) | 478 (108–1500) | 513 (144–1500) |

Alb albumin, Hb hemoglobin, ECOG PS Eastern Cooperative Oncology Group performance score

*Oral care delivered by dental professionals
group, and 66.6 μg/dL (95% CI, 63.0–70.2 μg/dL) in the polaprezinc group. The mean serum zinc levels at baseline were similar in each group and below the normal limit of 80 μg/dL.

**Zinc supplementation**

Zinc supplementation was successfully achieved for 12 weeks by 53 patients in the polaprezinc group and 46 patients in the zinc acetate hydrate group. The reasons for discontinuation were mostly unrelated to zinc therapy and included exacerbation of the primary disease (four patients in each group), cholangitis (two patients in the zinc acetate hydrate group), self-decision (two patients in the polaprezinc group and six patients in the zinc acetate hydrate group), or physician’s opinion (one patient in zinc acetate hydrate group). Discontinuation due to chest discomfort related to zinc supplementation was observed in one patient in the zinc acetate hydrate group. The mean number of days on medication for patients who discontinued was 57.8 days (95% CI, 39.9–75.7) in the polaprezinc group and 34.1 days (95% CI, 24.8–43.5) in the zinc acetate hydrate group.

**Changes in serum zinc levels**

The mean serum zinc levels at each evaluation time point are shown in Fig. 1. In the zinc acetate hydrate and polaprezinc groups, there was a significant increase in serum zinc levels at 6 weeks ($P < 0.001$, respectively; Wilcoxon’s signed rank test), which was maintained until 12 weeks. The mean changes in serum zinc levels at 12 weeks in the no intervention, zinc acetate, and polaprezinc groups were −3.8 μg/dL (95% CI, −8.7–1.1 μg/dL), 46.6 μg/dL (95% CI, 34.5–58.7 μg/dL), and 14.3 μg/dL (95% CI, 9.0–19.7 μg/dL), respectively. These results clearly demonstrate that serum zinc levels increased in a dose-dependent manner, and the increase in serum zinc in the group receiving zinc acetate hydrate and polaprezinc was statistically significant compared with that of the no intervention group ($P < 0.001$; Steel’s multiple comparison test).

**Changes in dysgeusia score**

Changes in dysgeusia determined using CTCAE and STTA score are shown in Fig. 2. At week 12, a total of 2, 8, and 2 patients were missing questionnaires in the no intervention, zinc acetate hydrate, and polaprezinc groups, respectively. The efficacy rate of the STTA score was 33.3% (17/51), 32.7% (17/52), and 52.6% (30/57) in the no intervention, zinc acetate hydrate, and polaprezinc groups, respectively, and there was no statistically significant difference between the groups ($P = 0.053$; chi-square test). The odds ratios of zinc acetate hydrate and polaprezinc to no intervention were 0.971 (95% CI, 0.427–2.209; $P = 0.945$) and 2.222 (95% CI, 1.018–3.850; $P = 0.045$). There was a statistically significant improvement in STTA score in the polaprezinc group compared with the no intervention group, but no statistical difference in the zinc acetate hydrate group compared with the no intervention group. The efficacy rates using the CTCAE score were 33.3% (17/51), 34.6% (18/52), and 36.8% (21/57) in the no intervention, zinc acetate hydrate, and polaprezinc groups, respectively, and there were no statistically significant differences between the groups ($P = 0.927$; chi-square test). The odds ratios of zinc acetate hydrate and polaprezinc compared with no intervention were 1.059 (95% CI, 0.468–2.394; $P = 0.891$) and 1.167 (95% CI, 0.528–2.578; $P = 0.703$), respectively. Changes in taste perception measured using CiTAS are shown in Online Resource 3. The mean changes of decline in basic taste using the CiTAS subscore were 0.16 (95% CI, −0.04–0.37), 0.36 (95% CI, 0.05–0.67), and 0.47 (95% CI, 0.26–0.68) in

![Fig. 1 Mean serum zinc levels determined at each evaluation time point](image-url)
the no intervention, zinc acetate hydrate, and polaprezinc groups, respectively. The mean changes in discomfort determined using the CiTAS subscore were $-0.03$ (95% CI, $-0.21$–$0.15$), $0.12$ (95% CI, $-0.09$–$0.33$), and $0.22$ (95% CI, $0.04$–$0.40$); phantogeusia and parageusia were $0.03$ (95% CI, $-0.16$–$0.22$), $0.13$ (95% CI, $-0.21$–$0.47$) and $0.21$ (95% CI, $-0.06$–$0.48$), and general taste alterations were $0.08$ (95% CI, $-0.09$–$0.26$), $0.35$ (95% CI, $0.04$–$0.65$), and $0.44$ (95% CI, $0.18$–$0.71$) in the no intervention, zinc acetate hydrate, and polaprezinc groups, respectively. There were no statistically significant differences between the groups. However, CTCAE, VAS, and CiTAS scores showed a trend toward improvement in dysgeusia in the polaprezinc group, but not the zinc acetate hydrate group, compared with the no intervention group.

**Factors related to improvement of dysgeusia**

Multivariate analysis was conducted using multiple regression analysis and logistic regression analysis to investigate independent factors related to improvement of dysgeusia. The results of logistic regression analysis for STTA are shown in Online Resource 4. Polaprezinc was analyzed as an independent significant factor for improvement in taste disorder ($P = 0.013$).

**Table 2** The results of QOL assessment using QOL-ACD

| Average (95% CI) | No intervention ($n = 51$) | Zinc acetate hydrate ($n = 52$) | Polaprezinc ($n = 57$) | $P$ value $^*$ | $P$ value $^*$ |
|------------------|---------------------------|---------------------------------|-----------------------|--------------|--------------|
| Daily activity   | $-1.41$ ($-2.80$–$-0.02$) | $-0.50$ ($-1.77$–$-0.77$)       | 0.686$^*$             | 0.00 ($-1.37$–$1.37$) | 0.414$^*$    |
| Physical condition | 0.08 ($-1.11$–$1.27$)    | 0.46 ($-0.64$–$1.57$)          | 0.938$^*$            | 1.12 ($-0.02$–$2.26$) | 0.454$^*$    |
| Psychological condition | $-0.63$ ($-1.66$–$-0.41$) | 0.19 ($-0.45$–$0.84$)         | 0.360$^*$             | 1.12 ($0.10$–$2.14$) | 0.049$^*$    |
| Social attitude  | 0.14 ($-0.91$–$1.19$)    | 0.63 ($-0.27$–$1.54$)          | 0.817$^*$            | 0.54 ($-0.42$–$1.51$) | 0.921$^*$    |
| Face scale       | $-0.31$ ($-0.60$–$-0.02$) | 0.19 ($-0.04$–$0.42$)         | 0.021$^*$             | 0.04 ($-0.21$–$0.28$) | 0.190$^*$    |
| Total            | $-2.14$ ($-5.50$–$1.22$) | 0.98 ($1.64$–$3.60$)           | 0.237$^*$             | 2.82 ($-0.36$–$6.01$) | 0.083$^*$    |

Note: $QOL$ quality of life, $QOL-ACD$ quality-of-life questionnaire for cancer patients treated with anticancer drugs, $CI$ confidence interval

$^*$Steel’s multiple comparison test

$^*$vs no intervention
Quality of life

The results of the QOL assessment by QOL-ACD are shown in Table 2. There was a significant improvement in psychological condition of QOL-ACD subdomain in the polaprezinc group compared with the no intervention group. There was a significant improvement in face scale in the QOL-ACD subdomain in the zinc acetate hydrate group compared with the no intervention group. However, in the other subdomains, there was no significant improvement in the zinc-treated group compared with the non-intervention group, and there was no significant improvement in total score. Therefore, QOL was not improved by zinc administration.

Discussion

This is the first large-scale, prospective, observational study of zinc supplementation therapy for chemotherapy-induced dysgeusia. Most patients undergoing chemotherapy with dysgeusia were zinc-deficient and showed a dose-dependent increase in serum zinc levels with zinc supplementation. However, there was no statistically significant improvement in dysgeusia in all assessment scores in the zinc acetate hydrate group, which showed the highest increase in serum zinc levels compared with the no intervention group. On the other hand, there was a statistically significant improvement in dysgeusia in the polaprezinc group compared with the no intervention group when assessed using the STTA criteria. Zinc therapy is commonly used for chemotherapy-induced dysgeusia. Importantly, elevated plasma zinc levels reportedly improved dysgeusia in patients without malignancy-related dysgeusia [21, 29]. However, the present study showed no significant correlation between elevated serum zinc levels and improvement in chemotherapy-induced dysgeusia. There was also no clinically significant improvement in QOL. This may be because chemotherapy-induced dysgeusia is caused by several factors, such as the neurotoxic effects of chemotherapy, loss of sense of smell, secretion of chemotherapy drugs and metabolites into the saliva, and taste bud dysfunction caused by inflammatory cytokines produced by cancer, in addition to zinc deficiency and abnormal growth and repair of taste bud cells [7, 30–32].

Fujii et al. [17] and Mizukami et al. [22] reported that polaprezinc improved chemotherapy-induced dysgeusia in a single-center, retrospective study. The present study also showed a significant improvement in taste using STTA score in the polaprezinc group as well as a trend toward improvement in CTCAE, VAS, and CiTAS scores. Although it is not clear why dysgeusia improved in the polaprezinc group, our results suggest the involvement of factors other than zinc supplementation via polaprezinc administration. Polaprezinc contains 78% l-carnosine as well as a varied zinc content. Carnosine is an endogenous dipeptide composed of β-alanine and l-histidine. Carnosine is present in many organisms, such as birds, fish, and mammals, including humans. It is abundantly present in skeletal muscle, and it is also observed in the stomach, kidneys, cardiac muscle, and brain. Carnosine has various advantageous characteristics, such as antiglycation and antioxidant properties, hydroxyl radical scavenging, maintenance of pH balance, enhanced wound healing, and chelation of metals including divalent zinc ion (Zn²⁺) and bivalent copper ion (Cu²⁺) [33–39]. Yehia et al. [40] reported that l-carnosine improved oxaliplatin-induced peripheral neuropathy in oxaliplatin-treated cancer patients. In that study, the anti-inflammatory effects of l-carnosine were confirmed by its ability to reduce nuclear factor kappa-light-chain-enhancer of activated B cells and tumor necrosis factor-alpha, and it showed antioxidant effects by enhancing nuclear factor-2 erythroid related factor-2 and reducing levels of malondialdehyde, showing anti-apoptotic effects by reducing caspase-3. Furthermore, carnosine synthase activity was 50- to 100-fold higher in the olfactory epithelium than in brain structures [41, 42]. Zinc-l-carnosine may have contributed to anti-inflammatory effects, enhancing healing of taste bud cells, protection from chemotherapy-induced neurotoxicity, and improvement of olfactory loss due to the added effects of carnosine. It remains unclear whether carnosine contributes to the improvement of dysgeusia.

In the present study, polaprezinc showed greater efficacy in chemotherapy-induced dysgeusia than zinc acetate hydrate. This may be due to limitations, such as a possible selection bias as this was not a randomized trial. In Japan, many patients with chemotherapy-induced dysgeusia do not undergo intervention owing to a lack of established treatment approaches for chemotherapy-induced dysgeusia. Therefore, we included the no intervention group as the observation group in the present study. However, as the therapeutic approach for dysgeusia was based on the decision of the attending physician, a certain degree of bias in the choice of treatment method cannot be denied. A greater understanding of these background characteristics and a validation study with a placebo control is warranted to understand the taste-improving effects of polaprezinc. To the best of our knowledge, no large-scale prospective study investigated chemotherapy-induced dysgeusia and appropriate intervention methods. Therefore, this study was designed as an exploratory investigation without blinding. The findings of the present study provide valuable data for future placebo-control trials.

Four assessment tools were used as taste assessment methods in the present study. All of the scales were subjective assessments using self-reporting in which the patients answered a questionnaire. Established objective methods include electrogustometry [43], filter paper disc method.
[44], and whole-mouth gustatory test [45], which are used in otolaryngology. Although these objective indices are effective in evaluating the detection and cognitive thresholds of taste, they cannot be used to assess subjective symptoms, such as hallucinations and cacophony, which are commonly observed in cancer patients undergoing chemotherapy. Chemotherapy-induced taste changes can be described as a complex experience that encompasses many factors, including changes in smell, touch, and preference. Therefore, the patient’s subjective symptoms are important. The scale used in the present study is a widely used, reliable, and valid tool for assessing patients’ subjective symptoms.

Based on the current study’s findings, we plan to conduct a double-blinded, randomized, controlled study using placebo, polaprezinc, and carnosine to evaluate the efficacy of polaprezinc and carnosine in chemotherapy-induced dysgeusia and to elucidate factors apart from zinc that may be involved in chemotherapy-induced dysgeusia. Taste evaluation methods such as electrogustometry, filter paper disc method, and whole-mouth gustatory test will also be considered.

Conclusions

In the present study, administration of polaprezinc or zinc acetate hydrate increased serum zinc levels; however, there was no significant correlation between the degree of serum zinc elevation and improvement of dysgeusia. Dysgeusia caused by chemotherapy may be a complex condition that involves factors other than zinc depletion.

Supplementary information

Ethics approval

All procedures were conducted in accordance with the ethical standards of the Helsinki Declaration of 1964 and its later versions. All patients received information about the study in written form and provided informed consent before enrollment. The study design and protocol were approved by the Institutional Review Board of Hokkaido University Hospital (approval number: 019–0248).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Patients signed informed consent regarding publishing their data.

Conflict of interest

The authors declare no competing interests.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1007/s00520-022-06936-4.

Acknowledgements

We thank the patients and their families for participating in this study, as well as the investigators, study coordinators, and medical staff at the 17 institutes. We also thank Enago (www.enago.jp) for their English language editing.

Author contributions

All authors contributed to the study conception and design. Data collection was performed by Ken Ito and SY, and analysis was performed by Ken Ito, Y. The first draft of the manuscript was written by Ken Ito, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by research funding from Nonprofit Organization (NPO), Hokkaido Gastrointestinal Cancer Study Group (HGCSG). All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Availability of data and material

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Holmes S (1993) Food avoidance in patients undergoing cancer chemotherapy. Support Care Cancer 1:326–330. doi:https://doi.org/10.1007/BF00364971
2. Bolting A, Keast R, Aranda S (2012) Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer 20:2765–2774. doi:https://doi.org/10.1007/s00520-012-1398-7
3. Epstein JB, Barash A (2010) Taste disorders in cancer patients: pathogenesis, and approach to assessment and management. Oral Oncol 46:77–81. doi:https://doi.org/10.1016/j.oraloncology.2009.11.008
4. Tomita H, Yoshikawa T (2002) Drug-related taste disturbances. Acta Otolaryngol Suppl:116–121. doi:https://doi.org/10.1080/00016480260046490
5. (2015) Japan Society of Clinical Oncology clinical practice guidelines for antiemetics. https://www.jsco-cgp.jp/item/29/index.html
6. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461. doi:https://10.1002/cncr.28592
7. Turcott JG, Juárez-Hernández E, De la Torre-Vallejo M, Sánchez-Lara K, Luvian-Morales J, Arrieta O (2016) Value: changes in the detection and recognition thresholds of three basic tastes in lung cancer patients receiving cisplatin and paclitaxel and its association with nutritional and quality of life parameters. Nutr Cancer 68:241–249. doi:https://10.1080/01635581.2016.1140757
8. Gumper EM, Giesinger JM, Oberguggenberger A, Kemmner G, Wintner LM, Gattringer K et al (2012) Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: prevalence, course of severity, and quality of life correlates. Acta Oncol 51:490–496. doi:https://doi.org/10.3109/0284166X.2011.633554
9. Zabernig A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer K et al (2010) Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 15:913–920. doi:https://doi.org/10.1634/theoncologist.2009-0333
10. Bernhardson BM, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16:275–283. doi:https://doi.org/10.1007/s00520-008-0319-7
11. Ishikawa T, Morita J, Kawachi K, Tagashira H (2013) Incidence of dysgeusia associated with chemotherapy for cancer. Gan To Kagaku Ryoho 40:1049–1054
12. Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E et al (1999) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–706
13. Suga Y, Kitade H, Kawagishi A, Takeda K, Haruki K, Ishizaki J et al (2011) Investigation for relation of gustatory and olfactory impairment in patients receiving cancer chemotherapy. Gan To Kagaku Ryoho 38:2617–2621
14. Sugawara S, Takimoto N, Iida A, Mori K, Sugiuura M, Yamamura K et al (2009) Incidence of taste disorder associated with cancer patients undergoing chemotherapy on an ambulatory basis. Gan To Kagaku Ryoho 36:1871–1876
15. Takimoto N, Sugawara S, Iida A, Sakakibara T, Mori K, Sugiuura M et al (2009) Development of taste disorders following FOLFOX-FOLFIIRI therapy and its effects on the QOL of patients with colorectal cancer. Gan To Kagaku Ryoho 36:431–435
16. Imai H, Soeda H, Komine K, Otsuka K, Shibata H (2013) Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliat Care 12:38. doi:https://doi.org/10.1186/1472-684X-12-38
17. Fujii H, Hirose C, Ishihara M, Iihara H, Imai H, Tanaka Y et al (2018) Improvement of dysgeusia by polaprezinc, a zinc-l-carnosine, in outpatients receiving cancer chemotherapy. Anticancer Res 38:6367–6373. doi:https://doi.org/10.21873/anticanres.12995
18. Kagawuchi M, Sawaki K, Okubo M, Sakai T, Shinomiya T, Kosuge Y (2006) Adverse drug reactions and oral disorders. Nihon Yakurigaku Zasshi 127:447–453. doi:https://doi.org/10.1254/rypj.127.447
19. Heckmann JG, Heckmann SM, Lang CJ, Hummel T (2003) Neurological aspects of taste disorders. Arch Neurol 60:667–671. doi:https://doi.org/10.1001/archneur.60.5.667
20. Henkin RI, Bradley DF (1970) Hypogeusia corrected by Ni++ and Zn++. Life Sci 11:970–709. doi:https://doi.org/10.1016/0024-3205(70)90278-x
21. Ikeda M, Kurono Y, Inokuchi A, Takeda N, Aiba T, Nomura Y et al (2013) The effect of zinc agent in 219 patients with zinc deficiency/inductive idiopathic taste disorder: a placebo controlled randomized study. Nihon Jibinnkoka Gakkai Kaiho 116:17–26. doi:https://doi.org/10.3950/jibinnkoka.116.17
22. Mizukami Y, Sato J, Nihei S, Kashiwaba M, Kudo K, Okuyama H et al (2016) The effectiveness of polaprezinc preparation for taste alteration in cancer chemotherapy. Gan To Kagaku Ryoho 43:979–983
23. Nakata Y, Hirashima T, Kondou Y, Tokuoya Y, Iwata K et al (2008) Involvement of zinc in taste disturbance occurring during treatment for malignant tumor in the chest and the effects of polaprezinc oral disintegrating tablets (a retrospective study). Gan To Kagaku Ryoho 35:955–959
24. Strasser F, Demmer R, Böhme C, Schmitz SF, Thuerlimmann B, Cerny T et al (2008) Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 13:337–346. doi:https://doi.org/10.1634/theoncologist.2007-0217
25. Epstein JB, de Andrade E Silva SM, Epstein GL, Leal JHS, Bara-
26. sch A, Smutzer G (2019) Taste disorders following cancer treatment: report of a case series. Support Care Cancer 27:4587–4595. doi:https://doi.org/10.1007/s00520-019-04758-5
27. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5 Quick_Reference_5x7.pdf
28. Saito T, Miyake M, Kawamori J, Fukushima S, Furuhashi S, Yoshinobu T et al (2002) Buccal mucosal cancer patient who failed to recover taste acuity after partial oral cavity irradiation. Radiat Med 20:257–260
29. Kano T, Kanda K (2013) Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum 40:E79–85. doi:https://doi.org/10.1188/13.ONF.E79-E85
30. Sakagami M, Ikeda M, Tomita H, Ikui A, Aiba T, Takeda N et al (2009) A zinc-containing compound, polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study. Acta Otolaryngol 129:1115–1120. doi:https://doi.org/10.1080/00016480802552550
31. Mazzeo MA, Linares JA, López MM, Bachmeier E, Wietz FM, Galván V et al (2013) Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system. J Oral Pathol Med 42:788–792. doi:https://doi.org/10.1111/jop.12078
32. Apis JK, Martens LC (2005) Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 150:119-131. doi:https://doi.org/10.1016/j.forsciint.2004.10.026
33. Wang H, Zhou M, Brand J, Huang L (2009) Inflammation and taste disorders: mechanisms in taste buds. Ann N Y Acad Sci 1170:596–603. doi:https://doi.org/10.1111/j.1749-6632.2009.04480.x
34. Vistoli G, Straniero V, Pedretti A, Fumagalli L, Bolchi C, Pallavicini M et al (2012) Predicting the physicochemical profile of diastereoisomeric histidine-containing dipeptides by property space analysis. Chirality 24:566–576. doi:https://doi.org/10.1002/chir.22056
35. Sale C, Saunders B, Harris RC (2010) Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. Amino Acids 39:321–333. doi:https://doi.org/10.1007/s00726-009-0443-4
36. Klebanov GI, Teselkin YO, Babenkova IV, Popov IN, Levin G, Tyulina OV et al (1997) Evidence for a direct interaction of superoxide anion radical with carnosine. Biochem Mol Biol Int 43:99–106. doi:https://doi.org/10.1016/S0273-7289(00)20086-0
37. Fitzpatrick DW, Fisher H (1982) Carnosine, histidine, and wound healing. Surgery 91:56–60
38. Numata Y, Terui T, Okuyama R, Hirasawa N, Sugiuera Y, Miyoshi I et al (2006) The accelerating effect of histamine on the cutaneous wound-healing process through the action of basic fibroblast growth factor. J Invest Dermatol 126:1403–1409. doi:https://doi.org/10.1038/sj.jid.5700253

39. Nagai K, Suda T, Kawasaki K, Mathura S (1986) Action of carnosine and beta-alanine on wound healing. Surgery 100:815–821

40. Yehia R, Saleh S, El Abhar H, Saad AS, Schaalan M (2019) L-carnosine protects against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a perspective on targeting Nrf-2 and NF-κB pathways. Toxicol Appl Pharmacol 365:41–50. doi:https://doi.org/10.1016/j.taap.2018.12.015

41. Harding J, Margolis FL (1976) Denervation in the primary olfactory pathway of mice. III. Effect on enzymes of carnosine metabolism. Brain Res 110:351–360. doi:https://doi.org/10.1016/0006-8993(76)90407-8

42. Kish SJ, Perry TL, Hansen S (1979) Regional distribution of homocarnosine, homocarnosine-carnosine synthetase and homocarnosinase in human brain. J Neurochem 32:1629–1636. doi:https://doi.org/10.1111/j.1471-4159.1979.tb02272.x

43. Krarup B (1958) Electro-gustometry: a method for clinical taste examinations. Acta Otolaryngol 49:294–305. doi:https://doi.org/10.3109/0016485809134758

44. Berling K, Knutsson J, Rosenblad A, von Unge M (2011) Evaluation of electrogustometry and the filter paper disc method for taste assessment. Acta Otolaryngol 131:488–493. doi:https://doi.org/10.3109/00016489.2010.535850

45. Yamauchi Y, Endo S, Sakai F, Yoshimura I (2002) A new whole-mouth gustatory test procedure. 1. Thresholds and principal components analysis in healthy men and women. Acta Otolaryngol Suppl:39–48. doi:https://doi.org/10.1080/00016480260046409

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Ken Ito1,2 · Satoshi Yuki3 · Hiroshi Nakatsum1 · Yasuyuki Kawamoto1 · Kazuaki Harada2 · Shintaro Nakano2 · Rika Saito1 · Takayuki Ando4 · Kentaro Sawada5 · Masataka Yagisawa6 · Atsushi Ishiguro7 · Masayoshi Dazai8 · Ichiro Iwanaga9 · Kazuteru Hatanaka10 · Atsushi Sato11 · Ryusuke Matsumoto12 · Yoshiaki Shindo13 · Miki Tateyama14 · Tetsuhiro Muranaka15 · Masaki Katagiri16 · Isao Yokota17 · Yuh Sakata18 · Naoya Sakamoto3 · Yoshito Komatsu1

1 Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan
2 Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
3 Department of Gastroenterology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
4 Third Department of Internal Medicine, University of Toyama, Toyama, Japan
5 Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan
6 Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Kitami, Japan
7 Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan
8 Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan
9 Department of Medical Oncology, Sapporo Kosei Hospital, Sapporo, Japan
10 Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan
11 Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
12 Department of Gastroenterology, Obihiro Kosei Hospital, Obihiro, Japan
13 Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan
14 Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan
15 Department of Gastroenterology, Wakkana City Hospital, Wakkana, Japan
16 Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan
17 Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
18 Misawa City Hospital, Misawa, Japan